Skip to content
    ARDX
    Earnings call· Jun 2026(Q2 FY26)

    ARDELYX Q2 FY26 earnings call ARDX

    Aug 6, 2026 Source

    Executive summary

    Ardelyx Q2 FY26 — Record Revenue, Revised Guidance Amid Payer Hurdles

    Ardelyx reported record Q2 FY26 revenue, driven by strong demand for Izrella and Xposa, but revised its full-year Izrella guidance downward due to unexpected payer hurdles impacting patient access. The company is implementing proactive measures to address these challenges and remains committed to its path to profitability in 2027, while also advancing its pipeline and maintaining financial strength.

    Highlights

    5

    • Combined revenue of $118 million, up 31% year-over-year, marking the largest quarterly revenue in company history.

    • Izrella revenue grew 33% year-over-year to $86.2 million, driven by strong demand.

    • Xposa revenue increased 27% year-over-year to $31.9 million, demonstrating resilience.

    • Ended Q2 with robust liquidity of $281.8 million in cash, cash equivalents, and short-term investments.

    • Net loss narrowed to $16.7 million in Q2 2026, compared to $19.1 million in the same period last year.

    Concerns

    4

    • Performance fell short of expectations due to significant payer hurdles impacting new patient starts and access to Izrella.

    • Full-year 2026 guidance for Izrella was lowered to a range of $350 million to $370 million.

    • Long-term $1 billion revenue target for Izrella is being re-evaluated for timing.

    • Long-term $750 million revenue guidance for Xposa was withdrawn due to market uncertainty.

    Guidance & targets

    6
    CategoryTargetConfidence
    Full-year 2026 Izrella revenue
    $350M-$370M
    high materiality
    High
    Full-year 2026 Xposa revenue
    $110M-$120M
    medium materiality
    High
    Full-year 2026 OPEX
    Below $500M
    high materiality
    High
    Long-term Izrella revenue
    $1B
    high materiality
    Medium
    Long-term Xposa revenue
    Withdrawn
    high materiality
    Low
    Sustainable profitability
    2027
    high materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Izrella
    Primary growth engine, experienced significant payer hurdles impacting new patient starts, but demand remains strong.
    Highest demand quarter to dateStrong growth in refills and total prescriptionsHigher fulfillment rates and faster fills through IPNOne additional refill per patient annually through IPNRecord highs in Q2 demand, total riders, total prescriptions per rider, and market share since launch
    		$86.2M33%——
    Xposa
    Demonstrated resilience and solid growth across key metrics despite CMS lawsuit outcome.
    Total dispenses: 33% increasePaid prescriptions: 25% increaseHighest total riders per writer since Q1 2025
    		$31.9M27%——

    Operational metrics

    12
    Total product revenue
    $118M31% YoY vs $90M in Q2 FY25
    Q2 FY26

    Largest quarterly revenue in company's history.

    R&D expenses
    $26.1Mvs $15.7M in Q2 FY25
    Q2 FY26

    Primarily reflects development activities and patient enrollment costs for the Excel Phase III clinical trial.

    SG&A expenses
    $101.4Mvs $84M in Q2 FY25
    Q2 FY26

    Reflects deliberate investments to address access barriers and drive future adoption of Izrella.

    Net loss
    $16.7Mvs $19.1M in Q2 FY25
    Q2 FY26

    Includes $15.3 million for non-cash share-based compensation.

    Non-cash share-based compensation
    $15.3Mvs $11.7M in Q2 FY25
    Q2 FY26

    Included in net loss for Q2 2026.

    Cash, cash equivalents, and short-term investments
    $281.8M
    End of Q2 FY26

    Liquidity remains robust.

    SLR drawdown
    $50M
    Q2 FY26

    From existing arrangement with SLR for general corporate purposes and to enhance flexibility.

    Patients on secretagogue experiencing persistent symptoms
    77%
    Current

    Based on internal research, highlighting unmet need for IBSC patients.

    CKD patients on dialysis treated with phosphate lowering therapies
    80%
    Current

    Out of more than 550,000 adult patients with CKD on dialysis in the US.

    Net loss
    $38M
    Q1 FY26

    Compared to $16.7M net loss in Q2 FY26, showing narrowing losses.

    Sales force size
    144Expanded
    Q2 FY26

    Expanded to increase frequency of engagement with targeted high-writing HCPs.

    Gross-to-Net (GTN) guidance
    Low to mid-30s
    FY26

    Guidance still stands, factoring in mix (government/commercial), IRA inflation rebates, co-pay, and distribution discounts.

    Industry KPIs

    3
    MetricValueDetails
    Launch access metricsHigher fulfillment rates, faster fills, and in one additional refill per patient on an annual basis
    Therapeutic drug market shareRecord highs
    Prescription volume new startsStrong growth

    Risks & headwinds

    3
    Significant payer hurdles impacting Izrella access and new patient startsQ2 2026 and ongoing

    Performance fell short of expectations; full-year 2026 Izrella guidance lowered to $350M-$370M.

    Mitigation: Doubled field reimbursement team, reinforced Izrella Pharmacy Network (IPN), expanded sales force to 144 representatives, initiating new direct-to-consumer activities, engaging payer community.

    CMS lawsuit outcome affirming oral-only phosphate lowering drugs in the bundle for XposaJune 26 (DC Circuit Court of Appeals decision)

    No longer pursuing further litigation on this matter.

    Mitigation: Committed to ensuring patient access to Xposa, enhancing commercial approach, refining salesforce deployment, strengthening engagement with HCPs and dialysis organizations.

    Uncertainty in Xposa market dynamics (post-Tdapha period, new QIP, new binders)Ensuing months

    Withdrawal of $750 million long-term revenue guidance for Xposa.

    Mitigation: Revisiting internal assumptions and will provide a better-informed view after assessing market transitions.

    What to watch in Q3 FY26

    4

    Izrella patient access and new patient starts

    Back half of this year
    CurrentSlowed by increased payer step edits and stringent prior authorizations
    TargetAcceleration of demand and improved pull-through

    Why it matters

    Directly impacts Izrella revenue growth and achievement of revised guidance.

    So we feel confident around those four actions that we've put in place that we'll be able to accelerate demand as well as improve pull through as we go through the back half of this year.

    Q&A highlights

    6

    Can you discuss the underlying demand metrics for Izrella in Q2 and July, and how they support the revised full-year guidance, including the pushes and pulls factored in?

    Management confirmed strong refills and total prescriptions for Izrella, noting Q2 was the highest demand quarter to date. They highlighted the Izrella Pharmacy Network (IPN) for higher fulfillment and refills. All identified friction and current performance have been factored into the revised guidance.

    “So we feel confident around those four actions that we've put in place that we'll be able to accelerate demand as well as improve pull through as we go through the back half of this year, that we'll continue to be able to have that control growth that we expect.”

    asked by Ryan (for Ruana Ruiz, Lear Inc. Partners) · answered by Eric Foster

    2 min read5 chapters

    Detailed Narrative

    01

    Izrella Access Challenges and Mitigation Strategies

    Ardelyx reported that Izrella's performance fell short of expectations due to significant payer hurdles, including more step edits and stringent prior authorizations, which have slowed new patient starts. To address these challenges, the company has doubled its field reimbursement team, reinforced the Izrella Pharmacy Network (IPN) to improve fulfillment rates and adherence, expanded its sales organization to 144 representatives for increased HCP engagement, and is initiating new direct-to-consumer activities in the second half of the year to boost patient awareness and drive demand.

    02

    Xposa Market Dynamics and Guidance Withdrawal

    Despite strong Q2 performance, the company withdrew its long-term $750 million revenue guidance for Xposa. This decision follows the DC Circuit Court of Appeals affirming the dismissal of their lawsuit against CMS, meaning oral-only phosphate lowering drugs remain in the bundle. Management cited uncertainty around the post-Tdapha period, the implications of a new phosphorus quality measure (QIP), and the development of new binders as reasons to re-evaluate internal assumptions and provide a better-informed view in the future.

    03

    Pipeline Advancement and Intellectual Property

    Ardelyx is investing in its future by advancing Tanapanoor, a next-generation NHG3 inhibitor. The company is building a robust patent estate for Tanapanoor, anchored by multiple Orange Book listed patents, including the 299 patent, which provides protection through 2042. Additionally, the Excel Phase III clinical trial for CIC is on track, with enrollment progressing well, and data readout expected around a year from the call date, leveraging existing sales force synergies.

    04

    Financial Strength and Capital Allocation Priorities

    The company emphasized its strengthening balance sheet, disciplined expense management, and commitment to achieving sustainable profitability in 2027. Ardelyx ended Q2 with $281.8 million in cash and short-term investments and drew down $50 million from an existing arrangement to enhance flexibility. Capital allocation priorities remain consistent: accelerating Izrella growth, actively progressing the pipeline, and maintaining financial strength.

    05

    Business Development and Long-term Vision

    Ardelyx is actively pursuing business development opportunities to expand its pipeline, noting a substantial number of opportunities are being evaluated. Management expressed optimism about building the pipeline, leveraging the cash generated by commercial products. The company maintains its enthusiasm and belief in its competitive position and strategy, aiming to create long-term value for patients and shareholders.

    AI-generated summary of the company’s earnings call. Not investment advice.